Medios AG

ILM1

DE000A1MMCC8

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:07 06/02/2026 GMT			5-day change	1st Jan Change
16.30 ^EUR	+1.62%		+1.88%	+12.57%

01-23	MEDIOS : Berenberg reaffirms its Buy rating	ZD
01-19	Medios, Bedrocan International Sign Distribution Deal for Medicinal Cannabis Products	MT

Medios AG announced that it has received funding from Luxempart S.A.

Published on 06/19/2024

S&P Capital IQ

MEDIOS AG

+1.62%

LUXEMPART

0.00%

Medios AG announced a private placement that it has issued common shares to raise funds on June 20, 2024. The transaction included participation from new investor, Luxempart S.A.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	MEDIOS AG	16.30EUR	+1.62%	+1.88%	491M
	LUXEMPART	63.00EUR	0.00%	-1.56%	1.5B

Latest news about Medios AG

01-23	MEDIOS : Berenberg reaffirms its Buy rating	ZD
01-19	Medios, Bedrocan International Sign Distribution Deal for Medicinal Cannabis Products	MT
01-19	Medios AG Enters Market for Medicinal Cannabis	CI
11-12	Medios Breaks Out of Downtrend - Berenberg Sets Price Target at 27 Euros	DP
11-12	MEDIOS : Gets a Buy rating from Deutsche Bank	ZD
11-12	MEDIOS : Berenberg remains its Buy rating	ZD
11-11	Medios AG, Q3 2025 Earnings Call, Nov 11, 2025
11-11	MEDIOS : Warburg Research remains its Buy rating	ZD
11-11	Warburg Research leaves Medios at 'Buy' - target price €26	DP
11-11	Specialty Pharma Company Medios Outperforms Expectations	DP
11-11	Medios Shares Rebound Sharply Following Better-Than-Expected Financial Results	DP
11-11	Medios Benefits from Strong Pharmaceutical Sales - Forecast Confirmed	DP
11-11	Medios confirms FY outlook	RE
11-11	Medios AG Appoints Thomas Meier as A Member of the Executive Board, Effective February 1, 2026	CI
11-11	Medios AG Confirms Earnings Guidance for the Year 2025	CI
11-09	Medios AG Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
11-03	Medios Names Successor to Outgoing CEO	MT
11-03	MEDIOS : Berenberg gives a Buy rating	ZD
11-03	Medios Appoints Successor for Outgoing CEO	DP
11-03	Medios AG: Thomas Meier appointed as new CEO	RE
11-02	Medios AG Announces Executive Changes	CI
24/10/25	Medios AG says Bencis sells 6.7% stake in Medios to Janus Henderson	RE
16/10/25	Medios AG(XTRA:ILM1) added to Germany SDAX (Total Return) Index	CI
16/10/25	INDEX MONITOR: Medios replaces Ceconomy in the SDax	DP
14/10/25	Ceconomy to Exit SDax, Medios Set to Rejoin Amid JD.com Takeover	RE

Medios AG, formerly Crevalis Capital AG, is a Germany-based company offering solutions in pharma industry. The Company covers relevant aspects of supply chain like from pharmaceutical supply and manufacture of patient-specific therapies, including blistering and others. It operates in two segments Pharmaceutical supply which focuses on pharmaceutical wholesale with finished specialty pharma (high-priced drugs for rare and chronic diseases) medications including oncology, neurology, autoimmunology, ophthalmology, infectiology, hemophilia along with offering finished medicinal products; Patient-specific therapies focusing on pharmaceutical manufacturing of patient-specific preparations such as Cytostatic infusions, Antibody therapies, Virostatic and antibiotic medications, Parenteral nutrition solutions, Investigational medicinal products are among others. Its products and services include Patient health & protection and procedures & processes for patient care and digitalization of data.

Employees

999

Sector

Pharmaceuticals

Calendar

03-03 - Berenberg EU Opportunities Conference

More about the company